Fri, Jan 30, 2015, 8:25 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • jacosa jacosa Nov 15, 2013 9:05 AM Flag

    The Cell Therapeutics drug

    I just saw that they entered a partnership with Baxter to develop Pacritinib. With good study results, the drug could reach market in 2 years or a bit less.

    Interesting compound said to owe all its activity to JAK-2 inhibition (although it also inhibits FLT-3). Generally good pharmacology although the 400 mg/day dose is high enough to get you to look for off-target effects (and diarrhea is reported). Very distinct structure from most disclosed Intermune compounds suggests that some patients resistant to Jakafi may be helped.

    I don't think this is a threat to Jakafi's first-line status. The drug has very little anti-JAK1 activity, and Incyte results suggest that JAK1 is important in MF morbidity (feeling sick). There is no particular reason to expect one JAK2 inhibitor to be less myelosuppressive than another, so the low myelosuppression seen in early trials suggests that the drug is being under-dosed to avoid problems. In fact, a worrisome pneumonia signal is seen in early studies.

79.71-1.63(-2.00%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.